Z6尊龙凯时

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

IND Application for CARsgen’s Allogeneic CD19/CD20 CAR-T CT1190B Accepted

CARsgen’s CT0596 and CT1190B Abstracts Published on EHA Website

EHA Preview | CARsgen to Present Results on CT0596 and CT1190B at 2026 EHA Annual Congress

CARsgen Therapeutics Included in the Stock List Under the Southbound Stock Connect

CARsgen Therapeutics Announces 2025 Annual Results

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting